Clinical Scenario
A 36-year-old man who is enrolled in a master’s degree program presents to your office stating that he is having difficulty focusing and concentrating on class material, and is afraid he will not be able to graduate. He reports a history of attention-deficit/hyperactivity disorder (ADHD) that was successfully treated with amphetamines in middle and high school. You wonder if this patient would benefit from amphetamines as an adult.

Clinical Question
Are amphetamines effective for the treatment of adult ADHD?

Evidence-Based Answer
Amphetamines improve ADHD symptom severity but, when compared with placebo, they are associated with increased discontinuation rates because of adverse effects. There does not appear to be a difference among dosages or between the immediate- and sustained-release formulations.¹ (Strength of Recommendation: A, based on consistent, good-quality, patient-oriented evidence.)

Practice Pointers
ADHD is a neurodevelopmental disorder that typically begins in childhood and often persists into adulthood. Adults may demonstrate both hyperactivity and inattention. Symptoms of inattention, such as difficulty sustaining attention, dislike of tasks requiring attention, and easy distractibility, are more common than hyperactive symptoms in adults with ADHD.² The disorder affects an estimated 4.4 percent of adults in the United States,³ and has been associated with unemployment, divorce, depression, post-traumatic stress disorder, and substance abuse.⁴ Treatment has been associated with higher employment rates⁵ and reduced substance abuse.⁶ Some pharmacotherapies, notably bupropion (Wellbutrin), target ADHD and comorbid mood and anxiety disorders.⁷

This Cochrane review focused on the use of amphetamines (dextroamphetamine, lisdexamfetamine [Vyvanse], and mixed amphetamine salts) in seven trials with a total of 1,091 patients and a mean study length of 8.1 weeks.¹ Amphetamines improved ADHD symptom severity when compared with placebo in five out of six studies; when results were pooled, the standardized mean difference with treatment was −0.72 (95% confidence interval [CI], −0.87 to −0.57). In the four studies that incorporated a Clinical Global Impression–Improvement scale, more patients taking amphetamines achieved a score of “very much improved” or “improved” than did those taking placebo (pooled risk ratio [RR] = 2.30; 95% CI, 1.84 to 2.87). In the six studies that evaluated treatment retention, amphetamines were not associated with improved retention (pooled RR = 1.06; 95% CI, 0.96 to 1.18); on the other hand, in two of four studies, amphetamines were associated with an increase in drop-out rates secondary to adverse effects (pooled RR = 3.03; 95% CI, 1.52 to 6.05).

Common adverse effects of amphetamine use included dry mouth, decreased appetite, insomnia, and headache, as well as an increase in heart rate and blood pressure.⁸⁻¹⁰ Because of the effect of amphetamines had on...
Amphetamines improved short-term ADHD. The authors searched CENTRAL, PubMed, EMBASE, CINAHL, PsycINFO, ClinicalTrials.gov, UK Clinical Trials Gateway, and also references obtained from articles and experts in the field. The authors conducted the electronic searches on February 25, 2010.

**Selection Criteria:** Randomized controlled trials comparing the efficacy of amphetamine derivatives against placebo or an active intervention.

**Data Collection and Analysis:** Two authors extracted data from each of the included studies. The authors used the standardized mean difference (SMD) and the risk ratio (RR) to assess continuous and dichotomous outcomes, respectively. They conducted a stratified analysis to determine the influence of moderating variables. They assessed the trials for risk of bias and drew a funnel plot to investigate the possibility of publication bias.

**Main Results:** The authors included seven studies, which enrolled 1,091 participants. All studies were placebo-controlled and three included an active comparator: guanfacine, modafinil, and paroxetine. Most studies had short-term follow-up, with a mean study length of 8.1 weeks. Amphetamines improved ADHD symptom severity (SMD = −0.72; 95% confidence interval [CI], −0.87 to −0.57) but did not improve retention in treatment overall and were associated with an increased drop-out rate due to adverse events (RR = 3.03; 95% CI, 1.52 to 6.05). The three amphetamine derivatives investigated (dextroamphetamine, lisdexamphetamine, and mixed amphetamine salts) were all efficacious for reducing ADHD symptoms, but mixed amphetamine salts also increased retention in treatment. Different doses did not appear to be associated with differences in efficacy. The authors investigated immediate- and sustained-release formulations but found no differences between them on any outcome. When amphetamines were compared with other drug interventions, no differences were found. The authors did not find any study to be at low risk of bias overall, mainly because amphetamines have powerful subjective effects that may reveal the assigned treatment.

**Authors’ Conclusions:** Amphetamines improved short-term ADHD symptom severity. Mixed amphetamine salts also increased retention in treatment. Amphetamines were associated with higher attrition due to adverse events. The short study length and the restrictive inclusion criteria limit the external validity of these findings. Furthermore, the possibility that the results of the included studies were biased was high, which could have led to an overestimation of amphetamine efficacy.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army Medical Department or the U.S. Army Service at large.

Address correspondence to Aaron Saguil, MD, MPH, FAAFP, at aaron.saguil@us.army.mil. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.
There are insufficient high-quality studies to determine patient-oriented outcomes of weight loss for the treatment of fatty liver disease. Nonetheless, weight loss remains a reasonable goal because it may reduce liver inflammation and improve comorbidities. In two of the studies reviewed, liver enzyme levels were essentially halved in patients who lost weight with lifestyle changes. (Strength of Recommendation: C, based on consensus, disease-oriented evidence, usual practice, expert opinion, or case series.)

Practice Pointers
Nonalcoholic fatty liver disease encompasses a disease spectrum ranging from simple fatty liver to nonalcoholic steatohepatitis to end-stage cirrhosis. Experts consider steatosis in a person consuming less than 20 to 30 g of alcohol daily (i.e., 1.5 standard alcoholic beverages for women and two standard alcoholic beverages for men) to be a criterion for the diagnosis of nonalcoholic fatty liver disease.\(^1\) More than two-thirds of adults who are obese have fatty liver, and 20 percent may have nonalcoholic steatohepatitis.\(^2\) More than 90 percent of adults with morbid obesity have fatty liver, and almost one-half have nonalcoholic steatohepatitis.\(^3\) According to this Cochrane review, nonalcoholic fatty liver disease has been identified as a cause of cirrhosis, especially cryptogenic cirrhosis.

Weight loss currently has the most supporting evidence for improving liver enzyme levels, compared with other therapies.\(^1,4\) This Cochrane review analyzed seven randomized trials (373 participants) that investigated weight loss as a treatment for fatty liver disease. One study examined children; the other studies focused on adults. The intensity of lifestyle changes in the intervention groups and counseling in the placebo groups differed among studies. All but one trial were judged to be at high risk of bias, and comparisons were hindered by different end points. Only one trial reported histologic changes. Statistically significant reductions in alanine transaminase (ALT) levels were seen in the treatment arms of two of the four lifestyle intervention trials that measured liver enzyme levels (one of which was the study involving children). In these trials, lifestyle changes were associated with reductions in ALT levels (from 84 to 42 U per L [1.40 to 0.70 µkat per L] and from 152 to 63 U per L [2.54 to 1.05 µkat per L]), as well as appreciable weight loss (a loss of 19.33 lb [8.7 kg] and a two-point reduction in body mass index, respectively).

Orlistat (Xenical) was used for weight loss in two other studies, but there was no notable reduction in liver enzyme levels or body mass index compared with patients in placebo groups who were counseled on restrictive diets. However, both the orlistat and placebo groups achieved halving of liver enzyme levels and an approximate weight loss of 17.78 lb (8 kg).
In a 2004 meta-analysis, bariatric surgery was reported to resolve 77 percent of diabetes mellitus cases, 62 percent of hypertension cases, and 70 percent of hyperlipidemia cases. Although some experts believe that bariatric surgery may also improve fatty liver disease that accompanies metabolic syndrome, no clinical trials have been performed. In addition, there have been some reports of histologic deterioration with rapid weight loss after bariatric surgery, so these patients should be monitored closely.

Consensus guidelines on nonalcoholic fatty liver disease have been published in the Journal of Digestive Diseases and by the American Gastroenterological Association (AGA). The AGA recommends that the initial target weight loss be 10 percent of baseline weight at a rate of 1 to 2 lb (0.45 to 0.90 kg) per week. An algorithm for the workup of mildly elevated liver enzyme levels can be found at http://www.aafp.org/afp/2005/0315/p1105.html#afp20050315p1105-f1.

NATHAN HITZEMAN, MD, and SIJIE JOY SHEN, MD

Author disclosure: No relevant financial affiliations to disclose.

REFERENCES


Research essential to family medicine

The Annals of Family Medicine, a peer-reviewed clinical research journal, is dedicated to advancing knowledge essential to understanding and improving health and primary care. View the full content online at www.AnnFamMed.org, or order your print subscription online or by calling 1-800-274-2237, Ext. 5166.